News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Morphotek Inc. Receives $2.7M in Funding from the National Institute of Allergy And Infectious Diseases (NIAID) to Develop Therapeutic Antibodies Against Biowarfare Agents


10/3/2007 10:01:42 AM

EXTON, Pa.--(BUSINESS WIRE)--Morphotek, Inc., a subsidiary of Eisai Co., Ltd. announced today that the company has received $2.7M in funding from the National Institute of Allergy and Infectious Diseases (NIAID) to support the preclinical development of fully human therapeutic monoclonal antibodies (mAbs) capable of neutralizing the toxic effects of Staphylococcal enterotoxin B (SEB) in vivo. The development project is a defense initiative in the fight against biowarfare agents

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES